Patents by Inventor Julia Neugebauer

Julia Neugebauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240018225
    Abstract: The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 18, 2024
    Inventors: Julia Neugebauer, Barbara Bachler-Konetzki, Tanja Herrmann, Winfried Elis
  • Patent number: 11542329
    Abstract: The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: January 3, 2023
    Assignee: Morphosys AG
    Inventors: Kerstin Uhland, Julia Neugebauer, Steffen Runz
  • Patent number: 11472880
    Abstract: The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: October 18, 2022
    Assignee: MORPHOSYS AG
    Inventors: Thomas Tiller, Steffen Runz, Julia Neugebauer, Andreas Bültmann
  • Publication number: 20220298251
    Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
    Type: Application
    Filed: October 29, 2021
    Publication date: September 22, 2022
    Inventors: Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
  • Publication number: 20220135660
    Abstract: The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.
    Type: Application
    Filed: January 10, 2022
    Publication date: May 5, 2022
    Inventors: Julia NEUGEBAUER, Steffen RUNZ, Stefanie URLINGER
  • Publication number: 20220135658
    Abstract: The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 5, 2022
    Inventors: Julia NEUGEBAUER, Barbara BACHLER-KONETZKI, Tanja HERRMANN, Winfried ELLIS
  • Patent number: 11254734
    Abstract: The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: February 22, 2022
    Assignee: MORPHOSYS AG
    Inventors: Julia Neugebauer, Steffen Runz, Stefanie Urlinger
  • Publication number: 20210269540
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: December 18, 2020
    Publication date: September 2, 2021
    Inventors: Marta COSENZA, Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
  • Publication number: 20210214435
    Abstract: The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.
    Type: Application
    Filed: May 15, 2019
    Publication date: July 15, 2021
    Inventors: Kerstin UHLAND, Julia NEUGEBAUER, Steffen RUNZ
  • Patent number: 10899841
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: January 26, 2021
    Assignee: NOVARTIS AG
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • Publication number: 20200377594
    Abstract: The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
    Type: Application
    Filed: August 13, 2018
    Publication date: December 3, 2020
    Inventors: Thomas TILLER, Steffen RUNZ, Julia NEUGEBAUER, Andreas BÜLTMANN
  • Publication number: 20190345236
    Abstract: The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 14, 2019
    Inventors: Julia Neugebauer, Steffen Runz, Stefanie Urlinger
  • Publication number: 20190194341
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: March 6, 2019
    Publication date: June 27, 2019
    Inventors: Marta COSENZA, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximillan Woisetschlaeger
  • Publication number: 20190135931
    Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
    Type: Application
    Filed: November 8, 2018
    Publication date: May 9, 2019
    Inventors: Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • Publication number: 20180179290
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant and/or a free amino acid.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • Patent number: 9988443
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky, Julia Neugebauer, Steffen Runz
  • Patent number: 9988455
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Publication number: 20170260272
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: December 23, 2016
    Publication date: September 14, 2017
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Jennifer BROGDON, William DOLE, John TRAUGER, Yuting TANG, Julia NEUGEBAUER, Annika SCHMID
  • Patent number: 9562101
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: February 7, 2017
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Publication number: 20160368999
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger